Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Free Cash Flow (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Free Cash Flow for 7 consecutive years, with -$163.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 57.63% year-over-year to -$163.6 million, compared with a TTM value of -$652.1 million through Dec 2025, down 111.76%, and an annual FY2025 reading of -$652.1 million, down 111.76% over the prior year.
  • Free Cash Flow was -$163.6 million for Q4 2025 at Avidity Biosciences, down from -$161.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $19.9 million in Q4 2023 and bottomed at -$198.3 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$65.8 million, with a median of -$45.2 million recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 149.62% in 2023, then tumbled 622.44% in 2024.
  • Year by year, Free Cash Flow stood at -$27.9 million in 2021, then tumbled by 43.4% to -$40.0 million in 2022, then soared by 149.62% to $19.9 million in 2023, then crashed by 622.44% to -$103.8 million in 2024, then plummeted by 57.63% to -$163.6 million in 2025.
  • Business Quant data shows Free Cash Flow for RNA at -$163.6 million in Q4 2025, -$161.6 million in Q3 2025, and -$198.3 million in Q2 2025.